newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on